摘要
目的:探讨恩替卡韦治疗慢性乙型肝炎疗效。方法:选择240例患者进行研究,按照治疗方法不同分为实验组和对照组,采用SPSS13.0统计软件进行统计分析。结果:实验组与对照组HBeAg阴转率在各时间段比较不存在统计学意义(P>0.05),HBeAg阴转率实验组和对照组均在治疗后24周、治疗后48周分别与前一个观察时间段比较存在统计学意义(P<0.05),实验组与对照组HBV-DNA阴转率、血清ALT复常率、血清AST复常率在各时间段比较均存在统计学意义(P<0.05),HBV-DNA阴转率、血清ALT复常率、血清AST复常率实验组和对照组均在治疗后12周、治疗后24周、治疗后48周分别与前一个观察时间段比较存在统计学意义(P<0.05)。结论:采用恩替卡韦治疗慢性乙型肝炎疗效快速、安全性高且耐药率低。
Objective： To study entecavir in treating chronic hepatitis.Method： 240 cases of patients were studied,according to the different treatment methods,were divided into experimental group and control group,compared the effect of 2 groups.Result： HBeAg negative conversion rate in the experimental group and the control group were in the 24 weeks after treatment,after treatment and after 48 weeks respectively,and a comparison of observed time statistical significance（P 0.05）,the experimental group and the control group of HBV-DNA negative conversion rate,serum ALT recovery rate,serum AST recovery rate in the time comparisons were statistically significant（P 0.05）.Conclusion： The use of entecavir in treating chronic hepatitis B with fast,high safety and low resistance rate.
出处
《河北医学》
CAS
2012年第7期942-945,共4页
Hebei Medicine
